Stanford University

Verily, Duke and Stanford launch Project Baseline study

Thursday, April 20, 2017

Verily Life Sciences, an Alphabet company, in partnership with Duke University School of Medicine and Stanford Medicine, announced the initiation of the Project Baseline study, a longitudinal study that will collect broad phenotypic health data from approximately 10,000 participants, who will each be followed over the course of at least four years. The study is the first initiative of Project Baseline, a broader effort designed to develop a well-defined reference, or “baseline,” of health as well as a rich data platform that may be used to better understand the transition from health to disease and identify additional risk factors for disease. Beyond this initial study, Project Baseline endeavors to test and develop new tools and technologies to access, organize and activate health information.

[Read More]

Chan Zuckerberg Biohub names first cohort of engineers, scientists and technologists

Wednesday, February 8, 2017

The Chan Zuckerberg Biohub (CZ Biohub) has announced its first cohort of 47 CZ Biohub Investigators from the faculty of the University of California, Berkeley, Stanford University and the University of California, San Francisco. This group includes both highly accomplished senior professors as well as up-and-coming young faculty. Each of the CZ Biohub Investigators will receive a five-year appointment and up to $1.5 million in funding to conduct life science research in their respective areas of expertise.

[Read More]

Aduro Biotech licenses Stanford Neoantigen Identification Technology

Monday, January 23, 2017

Aduro Biotech, a biopharmaceutical company with three distinct immunotherapy technologies, has announced an exclusive license agreement with Stanford University for state-of-the-art neoantigen identification technology developed by Dr. Hanlee Ji, associate professor of medicine at Stanford. Aduro will leverage its proprietary live, attenuated double-deleted Listeria (LADD) immunotherapy platform to engineer personalized LADD-based cancer therapies (pLADD) encoding multiple neoantigens identified through this technology. The company plans to initially evaluate pLADD for the treatment of cancers of the gastrointestinal tract, including colorectal cancer, with a phase I clinical trial expected to be initiated in 2017.  

[Read More]

The long road of multiple sclerosis research

Monday, September 26, 2016

The Pulse on Global Trials by Matthew Howes

Multiple sclerosis (MS), a chronic, autoimmune, inflammatory neurological disease of the central nervous system, is the largest neuro disease affecting young people. In MS, the immune system attacks the protective sheath, called myelin, that covers nerve fibers. Communication between the brain and the body becomes disrupted and nerves become damaged.

[Read More]

Boehringer, Duke collaborate on IPF patient registry

Friday, August 26, 2016

Boehringer Ingelheim Pharmaceuticals and the Duke Clinical Research Institute (DCRI) have announced the expansion of the Idiopathic Pulmonary Fibrosis—PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.

[Read More]

NIH funds precision medicine research with a focus on health disparities

Friday, July 29, 2016

The National Institute on Minority Health and Health Disparities (NIMHD), part of the NIH, has committed approximately $31 million over five years, pending available funding, to launch a new program for Transdisciplinary Collaborative Centers (TCCs) for health disparities research exploring the potential for precision medicine to promote health equity and advance the science of minority health and health disparities.

[Read More]